NEW YORK (GenomeWeb) – Courtagen Life Sciences announced yesterday that it has signed an agreement to collaborate with Astellas Pharma for the early-stage development of therapeutics for mitochondrial disease.

Mitochondrial disease is a class of rare genetic disorders caused when cellular mitochondria do not properly produce energy. Its symptoms vary from patient to patient, but can include muscle weakness, neurological problems, developmental delays, and increased risk of infection.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

A new report highlights the potential threats posed by advances in synthetic biology, NPR reports.

A Bloomberg reporter tried to get her genetic data deleted, but found it's not so simple to do.

Johns Hopkins University's Steven Salzberg and his colleagues have come up with a new estimate for the number of human genes, Nature News reports.

In Genome Research this week: study of intra-tumor heterogeneity, workflow resources for EPIGEN-Brazil, and more.

Jul
10
Sponsored by
Qiagen

This webinar offers a look at how an advanced genetics laboratory implemented and validated a commercial bioinformatics system to help scale its operations.

Jul
11
Sponsored by
Genomenon

This webinar will discuss an approach for automating variant classification based on the American College of Medical Genetics and Genomics guidelines.

Jul
12
Sponsored by
Canon BioMedical

This webinar will discuss a project that is analyzing the “Human Brainome” – genome, transcriptome, proteome, and phenome interaction data -- to gain insights into Alzheimer’s disease pathogenesis.

Aug
20
Sponsored by
Canon BioMedical

This webinar will provide an overview of recent advances in single-cell RNA sequencing from the perspectives of three research organizations.